Background {#Sec1}
==========

Germline mutations in *BRCA1* and *BRCA2* genes have important implications for treatment of patients diagnosed with breast or ovarian cancers as well as unaffected carriers of these mutations. Various guidelines have been established to guide physicians as to which patients should be referred for germline genetic testing. The National Comprehensive Cancer Network (NCCN) guidelines which are developed in the United Sates are freely available to practitioners worldwide and include broad guidelines for mutation testing based on clinical criteria without a calculation of expected mutation frequency.

A number of on-line calculators for risk of mutation assessment, based on clinical data are also available and largely used by clinical genetics specialists. The Manchester Score is a simple scoring system using basic clinical data that has been validated in several European populations to estimate an individual's mutation risk and determine eligibility for genetic screening.

Patients with breast cancer in the Middle East, particularly in Lebanon, tend to present at a younger age with a median of 50 years compared with the median age at diagnosis of 63 years in Europe and North America \[[@CR1]\]. In Lebanon, the prevalence of *BRCA* mutation were reported to be 5.7% among a cohort of patients with breast cancer meeting high-risk criteria \[[@CR2]\]. In another study, it was found that 12.5% of referred subjects had deleterious *BRCA* mutation in a cohort of high risk individuals referred for genetic testing \[[@CR3]\].

In order to further explore the landscape of *BRCA* mutations in the Lebanese population, we have reviewed all cases referred for *BRCA* mutation testing at the American University of Beirut Medical Center (AUBMC), the largest tertiary referral center in the country. We also aimed at addressing the practice of referral for genetic testing and establishing whether clinician-friendly risk prediction models or guidelines could be helpful in identifying individuals meeting high-risk criteria in our population lacking access to genetic counselors \[[@CR4]\], specifically the Manchester Score and NCCN guidelines.

Methods {#Sec2}
=======

After Institutional Review Board (IRB) approval, we retrospectively reviewed the cases of all individuals referred for *BRCA* mutation testing at the Medical Genetics Unit of AUBMC from April 2011 to May 2016. Data regarding family history and the frequency and characteristics of *BRCA* variants were collected from medical charts in order to calculate the Manchester score for this cohort (Table [1](#Tab1){ref-type="table"}) \[[@CR5]\]. Receiver Operating Characteristics (ROC) analysis was used to determine the predictive performance of the scoring system to identify those at risk of harboring a pathogenic mutation. Criteria for genetic risk evaluation according to NCCN guidelines were taken from NCCN guidelines version 1.2017 ([www.nccn.org](http://www.nccn.org)).Table 1Manchester ScoreCancerGenderAge at diagnosisScoreBreast CancerFemale\< 3011Breast CancerFemale30--398Breast CancerFemale40--496Breast CancerFemale50--594Breast CancerFemale\> 592Breast CancerMale\< 6013Breast CancerMale\> 5910Ovarian CancerFemale\< 6013Ovarian CancerFemale\> 5910Pancreatic CancerBoth1Prostate CancerMale\< 602Prostate CancerMale\> 591

To put our findings in the context of the landscape of *BRCA* mutations in the wider Middle East, we conducted a literature review of the most recently published data from the region.

*BRCA1* and *BRCA2* analysis {#Sec3}
----------------------------

Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes, DNA extraction was performed using QiaAmp DNA Mini kit (Qiagen). Amplification of the target genes (*BRCA1* and *BRCA2*) was performed by polymerase chain reaction (PCR) with specific primers designed through Primer 3 \[[@CR6]\]. Amplified sequences were visualized on agarose gel 2% to check the efficiency of the PCR. The amplicons were then purified, sequenced and loaded on the Genetic Analyzer (Applied Biosystem ABI 3500). Obtained sequences were analyzed using Seqscape® v2.7 software and compared to the corresponding reference sequences (*BRCA1*: ncbi RefSeq NM_007294; *BRCA2*: ncbi RefSeq NM_000059.3). The significance of each variant found was determined referring to Clinvar database \[[@CR7]\].

Results {#Sec4}
=======

Patients and disease characteristics {#Sec5}
------------------------------------

We reviewed the results of 281 individuals from 269 families of whom 12 subjects were known to carry a specific mutation diagnosed in an outside laboratory. 97.5% were females and 2.5% were males. The mean age of the cohort was 47.9 years (range 15--86), 208 (74.02%) patients were diagnosed to have breast (194) or ovarian (12) cancer with 2 patients presenting with both simultaneously. The mean age of patients with a diagnosis of breast cancer was 47.7 years (Table [2](#Tab2){ref-type="table"}). Of the families referred because of a known mutation six out of twenty five (24%) of subjects were found to be positive for the specific mutation (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).Table 2Characteristics of patientsVariableNumber/PercentageNumber of patients281Number of Families269Age (mean, years)47.86 (15--86)Positive first-degree family history for Breast and/or Ovarian cancer165Positive personal history for Breast and/or Ovarian208Breast cancer only194Ovarian cancer only12Both ovarian and breast cancer2Mean age of BC diagnosis (years)47.71Families carriers of Deleterious Mutation10Table 3*BRCA1* gene mutation and VUS identified in our cohortNucleotide ChangeAA ChangeNomenclature ProteinNumber of families with history of mutationDeleterious c.131G \> Tp.Cys44PheC44F7 c.3436_3439delTGTTp.Cys1146Leufs3555del45 c.2158G \> Tp.Glu720TerE720X3 c.3679C \> Tp.Gln1227TerQ1227X1 c.679G \> Tp.Glu227TerE227X2 c.3381 T \> Gp.Tyr1127TerY1127X3 c.4096 + 1G \> AIVS11 + 1G \> A1 c.1039_1040delCTp.Leu347Valfs1158_1159delCT1VUS c.536A \> Gp.Tyr179CysY179C c.1456 T \> Cp.Phe486LeuF486 L4 c.1648A \> Cp.Asn550HisN550H c.804C \> Gp.Asn268LysN268K2 c.3526G \> Ap.Val1176IleV1176I1 c.107C \> Ap.Ser36TyrS36Y1 c.4132G \> Ap.Val1378IleV1378I2 c.3956G \> Tp.Gly1319ValG1319 V1 c.2617 T \> Cp.Ser873ProS873P1 c.488G \> Cp.Arg163ThrR163T1 c.346G \> Ap.Glu116LysE116K1 c.1717_1717delTp.Ser573HisFsX1863delT1Table 4*BRCA2* gene mutation and VUS identified in our cohortNucleotide ChangeAA ChangeNomenclature ProteinNumber of families with history of mutationDeleterious c.9257-1G \> AIVS24-1G \> A3 c.3189_3192delGTCAp.Ser1064Leufs3417del41 c.426-12_426-8del5IVS4-12del51VUS c.8775G \> Cp.Gln2925HisQ2925H1 c.1627C \> Ap.His543AsnH543N1 c.8687G \> Ap.Arg2896HisR2896H c.8548G \> Ap.Glu2850LysE2850K2 c.632-5 T \> CIVS7-5 T \> C1 c.9117 + 3A \> GIVS23 + 3A \> G1 c.3131G \> Tp.Cys1044PheC1044F1 c.7976 + 49A \> GIVS17 + 49A \> G1

Mutations {#Sec6}
---------

In this cohort of 281 patients referred for *BRCA* testing at AUBMC, we found 17 patients with *BRCA1* mutations and 4 patients with *BRCA2* mutations, as seen in Table [3](#Tab3){ref-type="table"} and Table [4](#Tab4){ref-type="table"}. Three common mutations (two *BRCA1* and one *BRCA2*) accounted for 54% of the pathogenic mutations found in this cohort.

The most common *BRCA1* mutation, c.131G \> T was found in 5 patients and is carried by 7 Lebanese families (2 patients with family history positive of the c.131G \> T mutation were found to be negative for the mutation). *BRCA1* 3555del4 mutation was also common, found in 4 patients and carried by 5 families. *BRCA1* E720X (c.2158G \> T), ranked third in frequency and was present in 2 patient and found in 3 families (Table [3](#Tab3){ref-type="table"}). In the *BRCA2* gene, the mutation IVS24-1G \> A, was found in 2 patients and carried by 3 families (Table [4](#Tab4){ref-type="table"}.) A number of Variant of Undetermined Significance (VUS) were identified in *BRCA1* and *2* (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).

NCCN guidelines and Manchester scores {#Sec7}
-------------------------------------

For the cohort of patients tested between 2014 and 2016 detailed family history was available. All patients positive for *BRCA1* or *2* mutations fit the NCCN guidelines for *BRCA* mutation screening. The Manchester Score for all tested individuals was calculated, it did not discriminate between positive and negative *BRCA* mutation test results in this cohort with the area under the ROC curve of 0.494 (95% CI 0.349--0.639). Mean Manchester Score in patients negative for a *BRCA* mutation was 12.15 and that of patients positive for *BRCA 1/2* mutations was 11.63 (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Performance of Manchester score in predicting likelihood of *BRCA* mutation:  The area under the ROC curve of 0.494 (95% CI 0.349--0.639)

Literature review of *BRCA* mutations in the MENA region {#Sec8}
--------------------------------------------------------

In order to put our data in to context, we reviewed the spectrum of mutations reported in the Middle East and North Africa (MENA) region, updating a previous review published in 2015 \[[@CR8]\].

Studies conducted in the MENA region in the past 3 years have reported a number of new mutations especially in Moroccan, Tunisian, Jordanian and Lebanese families. The most common mutations found in the MENA region are included in the Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} below.Table 5Studies examining *BRCA1* & *2* mutations in Middle East and North Africa region from 2015 to 2018RegionCase selectionGene region coveredDetection methodReferenceMENA173 breast cancer and ovarian cancerAllParallel sequencing\
Sanger sequencing\[[@CR17]\]Lebanon250 femalesAllSequencing\
MLPA\[[@CR2]\]Lebanon45 familiesAllSequencing\
Sanger validation\[[@CR15]\]Tunisia7 familiesAllSequencing\[[@CR18]\]Tunisia92 familiesReview\[[@CR11]\]Jordan100 BC femalesAll*BRCA* sequencing\[[@CR10]\]Saudi Arabia818 BC patientsAllCapture or Sanger sequencing\[[@CR19]\]Morocco6 families - 15 patientsAllNext generation sequencing\[[@CR13]\]Morocco40 patientsAllSequencing\[[@CR12]\]Morocco122 patientsc.1310_1313delAAGASanger sequencing\
Next generation sequencing\[[@CR20]\]Palestine875 patientsBROCA panelParallel Sequencing\[[@CR14]\]Saudi Arabia310 patients*BRCA1* and *BRCA2*Next generation sequencing\
Sanger sequencing\[[@CR9]\]Table 6Common genetic variant in the MENA region*BRCA1* or *2*Genetic VariantNumber of patients with the mutationReferenceJordan\[[@CR10]\]*BRCA2*c.2254_2257delGACT4c.6685G \> T2Dup exon 5--114c.8774A \> G2K3416E2Tunisia\[[@CR11], [@CR13]\]*BRCA1*c.211dupA8c.5266dupC5c.1309del44c.4041delAG2c.798_799delTT2 families*BRCA2*c.1542_1547delAAGA2c.7887_7888insA2c.1309del45Morocco\[[@CR12], [@CR13]\]*BRCA1*c.798_799delTT2c.5062_5064delGTT2*BRCA2*c.7710delA2c.7235insG7Algeria\[[@CR13]\]*BRCA1*c.798_799delTT2 familiesPalestine\[[@CR14]\]*BRCA2*c.2482delGACT6Lebanon\[[@CR2]\]& \[[@CR3], [@CR15]\]*BRCA1*c.131G \> T6*BRCA2*c.9257_1G \> A3Saudi Arabia\[[@CR9]\]*BRCA1*c.4136_4137delCT5c.4524G \> A5

In Saudi Arabia, the *BRCA1* c.4136_4137delCT and c.4524G \> A were identified as the two most common mutations each found in 5 patients out of 310 enrolled in the study, accounting for 30.4% of the total *BRCA* mutations found in the cohort tested \[[@CR9]\]. In Jordan, the *BRCA2* c.2254_2257delGACT and Dup exon 5--11 were the 2 most common mutations each found in 4 patients out of 100 females enrolled in the study, accounting for 40% of patients presenting with the *BRCA* mutation \[[@CR10], [@CR11]\]. In Tunisia, the c.211dupA was the most common mutation found in 8 patients out of 92 from unrelated families, 29.6% of all the *BRCA* mutations found in this study \[[@CR11]\]. In Morocco, several mutations were found, the most common being the c.7235insG in 2 different patients out of 40 study participants, 18.2% of the *BRCA* mutation carriers \[[@CR12]\] . The *BRCA1* c.798_799delTT was a common mutation in North Africa \[[@CR13]\], however this has not been identified in studies conducted in the Middle East, namely Lebanon, Jordan or Palestine. This mutation is the only one found in several countries in the MENA region, all the other new mutations were exclusive to one country with the exception of the c.131G \> T found in Lebanon and in one Palestinian patient \[[@CR14]\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Map of the MENA region with the different *BRCA* mutations identified

Discussion {#Sec9}
==========

In a population of high-risk individuals referred for genetic testing at our institution, the prevalence of *BRCA1/2* mutation was 7.8%. A c.131G \> T mutation was detected among 5/17 (28%) of individuals found to have a mutation in *BRCA1* and among 7/28 (25%) families. The c.131G \> T mutation has only recently been classified as pathogenic \[[@CR7]\] and can be considered as a founder mutation in the Lebanese population. It is present in a relatively large number of families in our study and has previously identified in other studies conducted in Lebanon \[[@CR2], [@CR3], [@CR15]\], and in a study conducted in Palestinians \[[@CR14]\]. All individuals referred for genetic testing fit the broad NCCN guidelines however in a resource-limited health-care system where genetic testing is not usually covered by third-party payers, as is the situation in Lebanon and many other countries, identifying the individuals at highest risk for priority testing is desirable. The *BRCA1* c.131G \> T and c.3436_3439delTGTT along with the *BRCA2* mutations account for 54% of the total *BRCA* mutations found in our cohort. In a resource limited environment, if the frequency of these mutations is validated in larger studies we could consider a cost-effective targeted screening test for these 3 common mutations as had been proposed in an Italian population harboring a founder mutation \[[@CR16]\].

The Lebanese population has limited access to clinical genetics specialists and information regarding genetic testing is usually delivered by other health-care professionals such as oncologists \[[@CR4]\]. The Manchester Score is a simple and accessible scoring system that has been used in Europe to identify individuals at high risk of harboring a *BRCA* mutation but has not been validated in the Middle Eastern population were the median age of diagnosis of breast cancer is significantly lower. In this cohort the Manchester score failed to discriminate between positive and negative tests. One of the limitations of this study is the size of the cohort and low absolute number of individuals tested and mutations identified. Another limitation is the retrospective nature of the data collection, although patients were prospectively assessed by a clinical geneticist at the time of testing. The relatively low rate of mutations in the *BRCA1* and *2* genes in this high-risk population with breast cancer diagnosed in the relatively young, suggests that mutations in other genes may be prevalent.

To give a broader perspective on our results, we reviewed the reported mutations in the MENA region (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). The founder mutation identified in our cohort seems to be unique to the Lebanese/Palestinian populations. An interesting finding is the mutual exclusivity of reported founder mutations in each of the countries in the region, with the exception of the *BRCA1* c.798_799delTT identified in several North African populations.

Conclusion {#Sec10}
==========

In a cohort of high-risk Lebanese individuals referred for genetic testing, pathogenic *BRCA1/2* mutations were detected in 7.8%. While all subjects fit current NCCN guidelines for testing, the Manchester score failed to discriminate between those with positive and negative test results in this study. The *BRCA1* mutation c.131G \> T was detected among 5/17 (29%) of individuals found to have a pathogenic *BRCA1* mutation in the cohort and can be considered a founder mutation in the Lebanese population. On review of recently published data regarding the landscape of *BRCA* mutations in the MENA, each region appears to have a unique spectrum of mutations. Further investigation of other genes involved in young-onset and familial breast cancer in Lebanon are ongoing.
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